Myelodysplastic Syndromes

December 11th 2024

The recommendations for surveillance account for newly identified hematopoietic malignancy predispositions (HMP) and HMP genes, as well as a greater understanding of the prevalence of germline variants putting children as an increased risk of MDS and other HMs.

November 29th 2024

High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of developing late subsequent leukemia.

November 27th 2024

The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

November 11th 2024

Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, according to researchers.